ZENBEXUS Doubles MRD-Negative CR to 41.1% in Phase 3 EXCALIBER-RRMM
BMY sits 45% above its 52-week low of $42.52 on light trading volume (0.1× avg).
Summary
Bristol Myers Squibb reported detailed Phase 3 EXCALIBER-RRMM data showing ZENBEXUS (iberdomide) plus daratumumab/dexamethasone achieved a 41.1% MRD-negative complete response rate versus 20.7% for DVd (p<0.0001) in 420 patients with relapsed/refractory multiple myeloma. Overall response rate was 88.9% vs 76.1%, and CR or better was 45.9% vs 24.9%. Safety showed higher Grade 3/4 neutropenia (84.3% vs 11.3%) but lower neuropathy (12.3% vs 42.6%). The co-primary endpoint of progression-free survival is still being evaluated. This follows the FDA's accelerated approval of ZENBEXUS in August 2026 based on MRD-negative CR, and these data strengthen the case for full approval and broader adoption. The high neutropenia rate is a manageable but notable toxicity that could affect real-world use. Confirmatory PFS results will be the key catalyst for conversion to full approval.
At the time of this announcement, BMY was trading at $61.73 on NYSE in the Life Sciences sector, with a market capitalization of approximately $126.1B. The 52-week trading range was $42.52 to $68.64. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.